Stay updated with breaking news from Charlesm Baum. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced a non-exclusive clinical collaboration...
Mirati Therapeutics to Take Part in the 42nd Annual Goldman Sachs Global Healthcare Conference News provided by Share this article Share this article SAN DIEGO, June 2, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will take part in a fireside chat at the 42nd Annual Goldman Sachs Global Healthcare Conference, which will be webcast on June 9. Charles M. Baum, M.D., Ph.D., president and chief executive officer, will answer questions about the company at 3:50 p.m. E.T./12:50 p.m. P.T. The webcast will be available through the "Inve...
/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an...
socaltech.com San Diego-based oncology therapeutics developer Mirati Therapeutics said this morning that it has received $65M in an upfront payment, as part of a deal with Chinese company Zai Lab. According to the to companies,t he two have entered into a collaboration to develop and commercialize Mirati's Adagrasib in Greater China. Mirati will receive $65M upfront, with up to approximately $273M in potential milestone payments and royalties. Charles M. Baum, M.D., Ph.D., is President and CEO of Mirati Therapeutics. The company's cancer treatment is aimed at treating patients with the KRAS...
Mirati Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Updates - Initiated potentially registration-enabling trials evaluating our investigational KRASG12C inhibitor, adagrasib, in lung and colorectal cancers, as monotherapy and with other agents - Plan to file an Investigational New Drug (IND) application in 2022 for our investigational KRASG12D inhibitor, MRTX1133 - Presented preclinical data at AACR 2021 on an investigational synthetic lethal methylthioadenosine (MTA) cooperative PRMT5 inhibitor News provided by Share this article Share this article SAN DIEGO...